Citigroup
KYMR icon

Citigroup’s Kymera Therapeutics KYMR Stock Holding History

Citigroup’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.02M Buy
12,264
+1,757
+17% +$139K ﹤0.01% 3104
2025
Q4 		$818K Buy
10,507
+3,601
+52% +$243K ﹤0.01% 3262
2025
Q3 		$391K Sell
6,906
-21,775
-76% -$982K ﹤0.01% 3695
2025
Q2 		$1.25M Sell
28,681
-52,391
-65% -$1.8M ﹤0.01% 3039
2025
Q1 		$2.22M Buy
81,072
+16,656
+26% +$607K ﹤0.01% 2605
2024
Q4 		$2.59M Buy
64,416
+29,852
+86% +$1.35M ﹤0.01% 2596
2024
Q3 		$1.64M Buy
34,564
+14,978
+76% +$661K ﹤0.01% 2840
2024
Q2 		$585K Sell
19,586
-201,325
-91% -$6.97M ﹤0.01% 3289
2024
Q1 		$8.88M Buy
220,911
+131,982
+148% +$4.72M 0.01% 1323
2023
Q4 		$2.26M Sell
88,929
-11,867
-12% -$212K ﹤0.01% 2136
2023
Q3 		$1.4M Sell
100,796
-7,772
-7% -$156K ﹤0.01% 2259
2023
Q2 		$2.5M Sell
108,568
-96,163
-47% -$2.76M ﹤0.01% 2006
2023
Q1 		$6.07M Buy
204,731
+72,647
+55% +$2.34M ﹤0.01% 1396
2022
Q4 		$3.3M Sell
132,084
-68,956
-34% -$1.84M ﹤0.01% 1715
2022
Q3 		$4.38M Buy
201,040
+10,239
+5% +$270K ﹤0.01% 1626
2022
Q2 		$3.76M Buy
190,801
+169,002
+775% +$3.95M ﹤0.01% 1697
2022
Q1 		$923K Sell
21,799
-59,852
-73% -$2.53M ﹤0.01% 3048
2021
Q4 		$5.18M Buy
81,651
+28,313
+53% +$1.65M ﹤0.01% 1803
2021
Q3 		$3.13M Sell
53,338
-30,127
-36% -$1.75M ﹤0.01% 2152
2021
Q2 		$4.05M Buy
83,465
+19,780
+31% +$859K ﹤0.01% 2082
2021
Q1 		$2.48M Buy
63,685
+61,653
+3,034% +$3.71M ﹤0.01% 2358
2020
Q4 		$126K Buy
+2,032
New +$99.1K ﹤0.01% 5351

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Citigroup's KYMR Position: Q1 2026 in Review

Citigroup increased its Kymera Therapeutics (KYMR) stake by 17% in Q1 2026, buying an estimated $139K and bringing the position to 12,264 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3104.

Citigroup first reported a position in KYMR in Q4 2020 and has held it in 22 quarters since. The position peaked at $8.88M in Q1 2024. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Citigroup held 12,264 shares of Kymera Therapeutics worth $1.02M as of Q1 2026.
  • Citigroup bought 1,757 Kymera Therapeutics shares in Q1 2026, an estimated $139K.
  • Kymera Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3104 holding.
  • Citigroup first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Citigroup's Kymera Therapeutics position peaked at $8.88M in Q1 2024.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.